What We’re Reading: ALS Drug Taken Off the Market; Red State Needle Exchange Support; Hepatitis C Cases Drop
The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
ALS Drug Relyvrio Will Be Taken Off the Market, Maker Says
Amylyx Pharmaceuticals, the maker of Relyvrio, the newest treatment approved for amyotrophic lateral sclerosis (ALS), announced on Thursday that it would withdraw the drug from the market due to negative clinical trial results, according to the
Trump’s Surgeon General Urges Red States to Support Needle Exchanges
Jerome Adams, former President Trump’s surgeon general, is advocating for conservative states to support needle exchanges as a strategy to reduce infectious disease transmissions and save lives during the fentanyl epidemic, according to
Health Officials Unsure if Drop in US Hepatitis C Cases Is a Blip or Trend
Federal health officials announced Wednesday that new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases, according to the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025